Papp-Wallace KM, Bethel CR, Caillon J, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-lactam-β-lactamase inhibitor combination. Antimicrob Agents Chemother. 2019;63(5):e00105-e119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Belley A, Morrissey I, Hawser S, et al. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam. J Glob Antimicrob Resist. 2021;25:93–101.

Article  CAS  PubMed  Google Scholar 

Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021;76(3):550–60.

Article  CAS  PubMed  Google Scholar 

Magill SS, O’Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021;72(10):1784–92.

Article  CAS  PubMed  Google Scholar 

Advani SD, Claeys K. Cefepime/enmetazobactam for complicated urinary tract infections. JAMA. 2022;328(13):1299–301.

Article  PubMed  Google Scholar 

Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, et al. Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2022;66(2): e0167621.

Article  PubMed  Google Scholar 

European Medicines Agency. Cefepime/enmetazobactam: EU prescribing information. 2024. https://www.ema.europa.eu/. Accessed 11 Apr 2024.

Allecra Therapeutics. Cefepime/enmetazobactam: US prescribing information. 2024. https://www.fda.gov/. Accessed 26 Feb 2024.

Allecra Therapeutics. Allecra Therapeutics announces US FDA approval for EXBLIFEP® for the treatment of complicated urinary tract infections [media release]. 27 Feb 2024. https://www.allecra.com. Accessed 27 Feb 2024.

US Food & Drug Administration. Exblifep (cefepime and enmetazobactam): approval letter. 2024. https://www.fda.gov/. Accessed 20 Mar 2024.

ADVANZ PHARMA Limited, Allecra Therapeutics. ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections [media release]. 27 Mar 2024. https://www.advanzpharma.com/. Accessed 27 Mar 2024.

European Medicines Agency. Cefepime/enmetazobactam: EU assessment report. 2024. https://www.ema.europa.eu/. Accessed 11 Apr 2024.

Allecra Therapeutics. Allecra Therapeutics and ADVANZ PHARMA sign exclusive license and supply agreement for Allecra’s antibiotic cefepime/enmetazobactam in Europe [media release]. 13 Jan 2022. https://www.allecra.com. Accessed 13 Jan 2022.

Allecra Therapeutics GmbH, Shanghai Haini Pharmaceutical Co Ltd. Allecra Therapeutics and Shanghai Haini Pharmaceutical announce exclusive licensing agreement for cefepime/enmetazobactam for Greater China [media release]. 21 Dec 2020. https://www.allecra.com. Accessed 21 Dec 2020.

Orchid Chemicals & Pharmaceuticals. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics [media release]. 18 Apr 2013. https://www.orchidpharma.com. Accessed 18 Apr 2013.

Principe L, Lupia T, Andriani L, et al. Microbiological, clinical, and PK/PD features of the new anti-Gram-negative antibiotics: β-lactam/β-lactamase inhibitors in combination and cefiderocol—an all-inclusive guide for clinicians. Pharmaceuticals (Basel). 2022;15:463.

Article  CAS  PubMed  Google Scholar 

Morrissey I, Magnet S, Hawser S, et al. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from US and European hospitals during 2014–2015. Antimicrob Agents Chemother. 2019;63(7):e00514-e519.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tselepis L, Langley GW, Aboklaish AF, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(1): 105925.

Article  CAS  PubMed  Google Scholar 

Hawser S, Morrissey I, Kothari N, et al. Influence of genotype on the activity of cefepime/enmetazobactam against beta-lactam resistant Enterobacterales collected from Europe in 2019-2021 [abstract and poster no. P0097]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023.

Knechtle P, Shapiro S, Morrissey I, et al. Sigmoid Emax modeling to define the fixed concentration of enmetazobactam for MIC testing in combination with cefepime. Antimicrob Agents Chemother. 2021;65(8): e0092621.

Article  PubMed  Google Scholar 

Belley A, Kothari N, Monti F, et al. Antibacterial activity of cefepime/enmetazobactam and comparator agents against US enterobacterales clinical isolates collected from 2019–2021. Open Forum Infect Dis. 2023;10(Suppl 2):S60–70.

Google Scholar 

Hawser S, Morrissey I, Kothari N, et al. Surveillance of cefepime/enmetazobactam against European isolates of Enterobacterales collected between 2019 and 2021, including cephalosporin-resistant phenotypes [Abstract and poster no. P0289]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023.

Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015;59(5):2688–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernhard F, Odedra R, Sordello S, et al. Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2020;64(6):e00078-e120.

Article  PubMed  PubMed Central  Google Scholar 

Johnson A, McEntee L, Farrington N, et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-β-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e00180-e220.

Article  PubMed  PubMed Central  Google Scholar 

Das S, Fitzgerald R, Ullah A, et al. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother. 2020;65(1):e01468-e1520.

Article  PubMed  PubMed Central  Google Scholar 

Carmeli Y, Knechtle P, Hardenberg J, et al. A randomized phase 2 study of cefepime combined with the novel extended spectrum β-lactamase inhibitor enmetazobactam in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) [abstract no 1479]. OFID. 2019;6(Suppl 2):S539.

Article  PubMed Central  Google Scholar